|
|
Article: Results of Palatin Technologies' PT-141 Phase 2b Study in Men with Erectile Dysfunction to be Presented at American Urological Association Annual Meeting.
- Article from:
- Business Wire
- Article date:
- May 10, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
CRANBURY, N.J.--(BUSINESS WIRE)--May 10, 2004
Palatin Technologies, Inc. (AMEX:PTN) is pleased to announce that Hunter Wessells, M.D., FACS, Associate Professor with the Urology Clinic of the University of Washington, Harborview Medical Center, will present the results of its PT-141 Phase 2b study at the American Urological Association (AUA) Annual Meeting. The meeting is taking place in San Francisco May 8 - 13, 2004.
The presentation is titled "At-home Efficacy of an Intranasally Administered Melanocortin Receptor Agonist, PT-141, in Men with Erectile Dysfunction." Dr. Wessells will present at a podium ...